XML 96 R59.htm IDEA: XBRL DOCUMENT v2.4.1.9
Discontinued Operations (Details) (USD $)
3 Months Ended 12 Months Ended 0 Months Ended
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Jan. 15, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                          
Cash proceeds from divestitures, net                 $ 7,700,000us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested $ 104,718,000us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested $ 0us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested $ 9,646,000us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested  
(Loss) income from discontinued operations (net of tax) (1,058,000)us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax [1] (6,679,000)us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax [1] (60,025,000)us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax [1] (1,769,000)us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax [1] (886,000)us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax 531,000us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax 2,628,000us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax 1,835,000us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax   (69,531,000)us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax 4,108,000us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax 4,281,000us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax  
Loss on disposal of businesses                   85,515,000us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges 0us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges 0us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges  
Antioxidant, Ibuprofen and Propofol Assets - Discontinued Operations                          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                          
Cash proceeds from divestitures, net                   104,700,000us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
     
Net sales                   154,273,000us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
222,146,000us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
226,266,000us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
 
(Loss) income from discontinued operations                   (90,439,000)us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
5,985,000us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
6,381,000us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
 
Income tax (benefit) expense                   (20,908,000)us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
1,877,000us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
2,100,000us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
 
(Loss) income from discontinued operations (net of tax)                   (69,531,000)us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
4,108,000us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
4,281,000us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
 
Loss on disposal of businesses                   85,500,000us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
     
Loss on disposal of businesses, net of tax                   65,700,000alb_GainLossonSaleofAssetsandAssetImpairmentChargesnetoftax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
     
Cumulative foreign currency translation gains included in pre-tax impairment charge                   17,800,000us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
     
Discontinued Operations | Antioxidant, Ibuprofen and Propofol Assets - Discontinued Operations                          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                          
Post-closing adjustment, cash received                         $ 7,600,000us-gaap_ProceedsFromDivestitureOfBusinesses
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SegmentDiscontinuedOperationsMember
[1] Included in Loss from discontinued operations (net of tax) for the year ended December 31, 2014 is $(65.7) million related to the loss on the sale of our antioxidant, ibuprofen and propofol businesses and assets, the majority of which was recorded in the second quarter. See Note 2, “Discontinued Operations.”